A Top UK Midcap Performer’s US Plans Help it Evade Tariff Glare
PositiveFinancial Markets

A leading provider of cell and gene therapy services is shining in the UK midcap stock market this quarter, thanks to its expanding manufacturing operations in the US. This strategic move has allowed the company to sidestep the impact of tariffs imposed by President Donald Trump, showcasing how adaptability can lead to success in challenging economic climates.
— Curated by the World Pulse Now AI Editorial System